Bloomington, Ind. – Today a jury returned a verdict in the first bellwether trial on IVC filters. An Evansville, Indiana, jury returned a unanimous verdict in favor of Cook after a three week trial.
“We are pleased with this outcome. Our IVC filters are clinically successful devices critical to patient well-being,” said Mark Breedlove, vice president of the vascular division at Cook Medical. “We are dedicated to providing life-saving treatment options for patients and will continue to vigorously defend our IVC filters in future trials.”
Physicians and companies like Cook worked together to develop vena cava filters to help patients and reduce the risk of deadly pulmonary embolisms. IVC filters are an important option for physicians working to prevent the estimated 100,000 deaths associated with pulmonary embolism each year in the U.S.
Filter implantation is an important treatment option intended to help prevent life-threatening pulmonary embolisms. Physicians choose to use IVC filters based on each patient’s need, knowing that every patient’s situation is different and individual factors and risks must be considered when evaluating treatment options.
About Cook Medical
Since 1963 Cook Medical has worked closely with clinicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at https://www.cookmedical.com/, and for the latest news, follow us on Twitter, Facebook and LinkedIn.